MY171945A - Compositions, formulations and methods for treating ocular diseases - Google Patents

Compositions, formulations and methods for treating ocular diseases

Info

Publication number
MY171945A
MY171945A MYPI2015002288A MYPI2015002288A MY171945A MY 171945 A MY171945 A MY 171945A MY PI2015002288 A MYPI2015002288 A MY PI2015002288A MY PI2015002288 A MYPI2015002288 A MY PI2015002288A MY 171945 A MY171945 A MY 171945A
Authority
MY
Malaysia
Prior art keywords
formulations
compositions
methods
ocular diseases
treating ocular
Prior art date
Application number
MYPI2015002288A
Other languages
English (en)
Inventor
Kevin Peters
Robert Shalwitz
John Junusz
Alexander Smith
Original Assignee
Aerpio Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aerpio Therapeutics Inc filed Critical Aerpio Therapeutics Inc
Publication of MY171945A publication Critical patent/MY171945A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
MYPI2015002288A 2013-03-15 2014-03-14 Compositions, formulations and methods for treating ocular diseases MY171945A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361792868P 2013-03-15 2013-03-15
US201361792679P 2013-03-15 2013-03-15
US201361882048P 2013-09-25 2013-09-25
US201361882056P 2013-09-25 2013-09-25
US201461934570P 2014-01-31 2014-01-31

Publications (1)

Publication Number Publication Date
MY171945A true MY171945A (en) 2019-11-08

Family

ID=51529957

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2015002288A MY171945A (en) 2013-03-15 2014-03-14 Compositions, formulations and methods for treating ocular diseases

Country Status (17)

Country Link
US (10) US9440963B2 (cg-RX-API-DMAC7.html)
EP (3) EP2967066B1 (cg-RX-API-DMAC7.html)
JP (3) JP6572201B2 (cg-RX-API-DMAC7.html)
KR (1) KR20150129019A (cg-RX-API-DMAC7.html)
CN (2) CN109925312A (cg-RX-API-DMAC7.html)
AU (2) AU2014233363B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015023753A2 (cg-RX-API-DMAC7.html)
CA (1) CA2903871A1 (cg-RX-API-DMAC7.html)
ES (2) ES2766326T3 (cg-RX-API-DMAC7.html)
GB (3) GB2540638B (cg-RX-API-DMAC7.html)
HK (2) HK1219836A1 (cg-RX-API-DMAC7.html)
IL (2) IL240786B (cg-RX-API-DMAC7.html)
MX (1) MX371382B (cg-RX-API-DMAC7.html)
MY (1) MY171945A (cg-RX-API-DMAC7.html)
PH (2) PH12015502153B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201507131WA (cg-RX-API-DMAC7.html)
WO (1) WO2014145068A1 (cg-RX-API-DMAC7.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2828739T3 (es) 2006-04-07 2021-05-27 Aerpio Pharmaceuticals Inc Anticuerpos que se unen a la proteína tirosina fosfatasa beta humana (HPTP-beta) y sus usos
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
US8569348B2 (en) 2009-07-06 2013-10-29 Aerpio Therapeutics Inc. Compounds, compositions, and methods for preventing metastasis of cancer cells
JP5777170B2 (ja) 2009-10-30 2015-09-09 アイエックス バイオファーマ リミテッド 速溶性固体剤形
US12186426B2 (en) 2009-10-30 2025-01-07 Ix Biopharma Ltd. Solid dosage form
PH12012500788A1 (en) 2009-11-06 2016-07-27 Aerpio Therapeutics Inc Compositions and methods for treating colitis
US20180092883A1 (en) * 2010-10-07 2018-04-05 Aerpio Therapeutics, Inc. Phosphatase inhibitors for treating ocular diseases
CN103347561B (zh) 2010-12-08 2016-09-07 康沃特克科技公司 用于评估伤口分泌液的集成系统
WO2012078784A1 (en) 2010-12-08 2012-06-14 Convatec Technologies Inc. Wound exudate system accessory
US20130095065A1 (en) 2011-10-13 2013-04-18 Aerpio Therapeutics, Inc. Methods for Treating Vascular Leak Syndrome and Cancer
BR112014008759A8 (pt) 2011-10-13 2017-09-12 Aerpio Therapeutics Inc Tratamento de doença ocular
CN104812378B (zh) * 2012-10-11 2017-12-01 Ix生物制药有限公司 固体剂型
US9440963B2 (en) * 2013-03-15 2016-09-13 Aerpio Therapeutics, Inc. Compositions, formulations and methods for treating ocular diseases
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
US9388135B2 (en) 2014-02-19 2016-07-12 Aerpio Therapeutics, Inc. Process for preparing N-benzyl-3-hydroxy-4-substituted-pyridin-2-(1H)-ones
EP3116503A4 (en) 2014-03-14 2017-08-23 Aerpio Therapeutics, Inc. Hptp-beta inhibitors
US9539245B2 (en) 2014-08-07 2017-01-10 Aerpio Therapeutics, Inc. Combination of immunotherapies with activators of Tie-2
EP3977994B1 (en) 2015-09-23 2024-04-24 EyePoint Pharmaceuticals, Inc. Activators of tie-2 for use in treating intraocular pressure
EP3364674B1 (en) * 2015-11-06 2019-10-09 Huawei Technologies Co., Ltd. Voice roaming method, mobility management network element, and access network element
SG11201900464TA (en) 2016-07-20 2019-02-27 Aerpio Therapeutics Inc HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß)
CN109996440A (zh) * 2016-10-21 2019-07-09 曼宁研究有限公司 Ve-ptp敲除
EP3856245A4 (en) 2018-09-24 2022-10-26 EyePoint Pharmaceuticals, Inc. MULTISPECIFIC ANTIBODIES THAT TARGET HPTP - ß (VE-PTP) AND VEGF
CA3137138A1 (en) * 2019-04-18 2020-10-22 EyePoint Pharmaceuticals, Inc. Methods of treating hypertension with activators of tie-2
EP3962482A4 (en) * 2019-04-29 2023-01-11 EyePoint Pharmaceuticals, Inc. TIE 2 ACTIVATORS FACING THE SCHLEMM CHANNEL
US11413242B2 (en) 2019-06-24 2022-08-16 EyePoint Pharmaceuticals, Inc. Formulations of Tie-2 activators and methods of use thereof
US11613534B2 (en) 2019-10-29 2023-03-28 EyePoint Pharmaceuticals, Inc. Small molecule activators of Tie-2
CN117460743A (zh) * 2020-06-16 2024-01-26 曼宁研究公司 小分子ve-ptp抑制剂
CA3202338A1 (en) * 2020-12-18 2022-06-23 EyePoint Pharmaceuticals, Inc. Methods for manufacture of small molecule activators of tie-2
WO2025128706A1 (en) * 2023-12-11 2025-06-19 Massachusetts Eye And Ear Infirmary Methods of using tie-2 activators

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5078486A (en) 1989-10-13 1992-01-07 Evans David W Self-calibrating vision test apparatus
US5688781A (en) * 1994-08-19 1997-11-18 Bristol-Myers Squibb Company Method for treating vascular leak syndrome
JP4122056B2 (ja) 1995-04-06 2008-07-23 リジエネロン ファーマシューティカルズ，インコーポレイテッド Ｔｉｅ−２リガンド、その作製方法および使用方法
US20030040463A1 (en) 1996-04-05 2003-02-27 Wiegand Stanley J. TIE-2 ligands, methods of making and uses thereof
US6455031B1 (en) * 1997-06-18 2002-09-24 David G Davies Methods and compositions for controlling biofilm development
US5980929A (en) 1998-03-13 1999-11-09 Johns Hopkins University, School Of Medicine Use of a protein tyrosine kinase pathway inhibitor in the treatment of retinal ischmemia or ocular inflammation
US5919813C1 (en) 1998-03-13 2002-01-29 Univ Johns Hopkins Med Use of a protein tyrosine kinase pathway inhibitor in the treatment of diabetic retinopathy
US6455035B1 (en) * 1999-03-26 2002-09-24 Regeneron Pharmaceuticals, Inc. Angiopoietins and methods of use thereof
EP1165115B1 (en) 1999-03-26 2003-05-28 Regeneron Pharmaceuticals, Inc. Modulation of vascular permeability by mean of tie2 receptor activators
US6924264B1 (en) 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
KR20080068151A (ko) 2000-06-23 2008-07-22 바이엘 쉐링 파마 악티엔게젤샤프트 ＶＥＧＦ/ＶＥＧＦ 수용체 및 안지오포이에틴/Ｔｉｅ수용체의 기능을 방해하는 조합 제제 및 조성물과 이들의용도 (Ⅱ)
US20040058956A1 (en) * 2000-12-11 2004-03-25 Yohko Akiyama Pharmaceutical composition having an improved water solubility
SE518981C2 (sv) 2000-12-14 2002-12-17 Shl Medical Ab Autoinjektor
US7166435B2 (en) * 2001-08-06 2007-01-23 The Quigley Corporation Compositions and methods for reducing the transmissivity of illnesses
US20030158199A1 (en) * 2002-01-25 2003-08-21 Kylix, B.V. Novel compounds for inhibition of Tie-2
AU2003231098A1 (en) 2002-04-25 2003-11-10 University Of Connecticut Health Center Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
US7507568B2 (en) 2002-09-25 2009-03-24 The Proctor & Gamble Company Three dimensional coordinates of HPTPbeta
US7226755B1 (en) 2002-09-25 2007-06-05 The Procter & Gamble Company HPTPbeta as a target in treatment of angiogenesis mediated disorders
EP1551425A4 (en) * 2002-10-09 2006-09-20 Kosan Biosciences Inc THERAPEUTIC FORMULATIONS
US6946479B2 (en) 2002-11-09 2005-09-20 The Procter & Gamble Company N-sulfonyl-4-methyleneamino-3-hydroxy-2-pyridones
US6930117B2 (en) 2002-11-09 2005-08-16 The Procter & Gamble Company N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones
AU2003292838A1 (en) * 2002-12-27 2004-07-29 Kirin Beer Kabushiki Kaisha Therapeutic agent for wet age-related macular degeneration
EP1611123B8 (en) * 2003-04-09 2013-11-13 Exelixis, Inc. Tie-2 modulators and methods of use
US20050186208A1 (en) * 2003-05-30 2005-08-25 Genentech, Inc. Treatment with anti-VEGF antibodies
US20050059639A1 (en) 2003-09-11 2005-03-17 Wei Edward T. Ophthalmic compositions and method for treating eye discomfort and pain
US7771742B2 (en) 2004-04-30 2010-08-10 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
WO2005118639A1 (en) * 2004-06-02 2005-12-15 Valtion Teknillinen Tutkimuskeskus Method for activating of t cell protein tyrosine phosphatase and therapeutical methods based thereon
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
US7893040B2 (en) 2005-07-22 2011-02-22 Oculis Ehf Cyclodextrin nanotechnology for ophthalmic drug delivery
US20080293691A1 (en) 2005-11-29 2008-11-27 Smithkline Beecham Corporation Treatment Method
EP3168234A1 (en) 2005-12-15 2017-05-17 Medimmune Limited Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or fltl antagonist for treating cancer
CN101415422B (zh) * 2006-02-09 2012-11-07 第一三共株式会社 抗癌药用组合物
ES2828739T3 (es) * 2006-04-07 2021-05-27 Aerpio Pharmaceuticals Inc Anticuerpos que se unen a la proteína tirosina fosfatasa beta humana (HPTP-beta) y sus usos
US20130023542A1 (en) 2006-06-27 2013-01-24 Aerpio Therapeutics Inc. Human protein tyrosine phosphatase inhibitors and methods of use
US8846685B2 (en) * 2006-06-27 2014-09-30 Aerpio Therapeutics Inc. Human protein tyrosine phosphatase inhibitors and methods of use
US7795444B2 (en) 2006-06-27 2010-09-14 Warner Chilcott Company Human protein tyrosine phosphatase inhibitors and methods of use
US7622593B2 (en) * 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
US7589212B2 (en) 2006-06-27 2009-09-15 Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
CN101583357B (zh) * 2006-08-29 2013-03-20 新加坡国立癌症中心 Mtor拮抗剂和血管生成抑制剂用于制备治疗癌症的药物的用途
US8957022B2 (en) 2006-10-27 2015-02-17 Sunnybrook Health Sciences Centre Multimeric tie 2 agonists and uses thereof in stimulating angiogenesis
ES2365931T3 (es) 2006-12-13 2011-10-13 Shl Group Ab Inyector automático.
AU2008231910B2 (en) 2007-03-23 2011-04-14 Shl Group Ab Auto injector
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
US11078262B2 (en) 2007-04-30 2021-08-03 Allergan, Inc. High viscosity macromolecular compositions for treating ocular conditions
WO2009007229A1 (en) 2007-07-06 2009-01-15 Shl Medical Ab One shot injector with dual springs
EP2192938B1 (en) 2007-09-18 2017-10-25 SHL Group AB Automatic injection device with needle insertion
EP2269621B1 (en) * 2008-03-31 2017-12-27 Shiseido Company, Ltd. Cinnamonum extract for treating photoaging
JP5167407B2 (ja) 2008-05-20 2013-03-21 エス・ホー・エル・グループ・アクチボラゲット 薬剤送達装置のための装置
US8075517B2 (en) 2008-06-11 2011-12-13 Shl Group Ab Medicament delivery device
KR101784645B1 (ko) * 2008-06-18 2017-10-11 가부시키가이샤 시세이도 림프관의 안정화제
WO2010010689A1 (ja) * 2008-07-22 2010-01-28 株式会社メニコン コンタクトレンズ用液剤
CN102246349A (zh) 2008-12-22 2011-11-16 株式会社藤仓 薄膜天线及其制造方法
US9096555B2 (en) 2009-01-12 2015-08-04 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome
DK2385763T3 (en) * 2009-01-12 2018-07-16 Aerpio Therapeutics Inc METHODS OF TREATING VASCULAR LEAK SYNDROME
US8569348B2 (en) 2009-07-06 2013-10-29 Aerpio Therapeutics Inc. Compounds, compositions, and methods for preventing metastasis of cancer cells
US8883832B2 (en) 2009-07-06 2014-11-11 Aerpio Therapeutics Inc. Compounds, compositions, and methods for preventing metastasis of cancer cells
TWI393578B (zh) 2009-07-07 2013-04-21 Shl Group Ab 注射裝置
TW201105363A (en) * 2009-07-14 2011-02-16 Univ Yamagata Eye drop for macular edema treatment
PH12012500788A1 (en) 2009-11-06 2016-07-27 Aerpio Therapeutics Inc Compositions and methods for treating colitis
JP2011201811A (ja) * 2010-03-25 2011-10-13 Shiseido Co Ltd Ｔｉｅ２活性化剤、血管の成熟化、正常化又は安定化剤、リンパ管安定化剤並びにしわ防止・改善剤及びむくみ改善・予防剤
US20110319455A1 (en) 2010-04-19 2011-12-29 Bruce Steven Klein Antifungal Treatment
CA2797247C (en) * 2010-04-28 2019-10-22 Sunnybrook Health Sciences Centre Methods and uses of tie2 binding and/or activating agents
US20180092883A1 (en) 2010-10-07 2018-04-05 Aerpio Therapeutics, Inc. Phosphatase inhibitors for treating ocular diseases
CA2818215C (en) 2010-10-07 2015-07-21 Aerpio Therapeutics Inc. Compositions and methods for treating ocular edema, neovascularization and related diseases
EP2857032A3 (en) * 2010-12-02 2015-07-15 Maruzen Pharmaceuticals Co., Ltd. Tie2 activator, vascular endothelial growth factor (vegf) inhibitor, anti-angiogenic agent, agent for maturing blood vessels, agent for normalizing blood vessels, agent for stabilizing blood vessels, and pharmaceutical composition
CN102532042A (zh) * 2010-12-30 2012-07-04 上海医药工业研究院 一种芳基脲类化合物、其中间体及其应用
CN103402582A (zh) * 2011-02-11 2013-11-20 普西维达公司 使用抗水肿疗法治疗黄斑水肿的方法
BR112014008759A8 (pt) 2011-10-13 2017-09-12 Aerpio Therapeutics Inc Tratamento de doença ocular
US20130095065A1 (en) 2011-10-13 2013-04-18 Aerpio Therapeutics, Inc. Methods for Treating Vascular Leak Syndrome and Cancer
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
US9440963B2 (en) 2013-03-15 2016-09-13 Aerpio Therapeutics, Inc. Compositions, formulations and methods for treating ocular diseases
WO2015002893A1 (en) 2013-07-02 2015-01-08 The Trustees Of Columbia University In The City Of New York Clearance of bioactive lipids from membrane structures by cyclodextrins
US9388135B2 (en) 2014-02-19 2016-07-12 Aerpio Therapeutics, Inc. Process for preparing N-benzyl-3-hydroxy-4-substituted-pyridin-2-(1H)-ones
EP3116503A4 (en) 2014-03-14 2017-08-23 Aerpio Therapeutics, Inc. Hptp-beta inhibitors
US9719135B2 (en) * 2014-07-03 2017-08-01 Mannin Research Inc. Conditional angiopoietin-1/angiopoietin-2 double knock-out mice with defective ocular drainage system

Also Published As

Publication number Publication date
AU2014233363A1 (en) 2015-10-22
US9440963B2 (en) 2016-09-13
EP2967066A1 (en) 2016-01-20
HK1219836A1 (zh) 2017-04-21
IL240786A0 (en) 2015-10-29
EP2967066B1 (en) 2019-10-23
SG11201507131WA (en) 2015-10-29
US12152023B2 (en) 2024-11-26
US20180022741A1 (en) 2018-01-25
AU2017235953A1 (en) 2017-10-19
JP2016516068A (ja) 2016-06-02
JP2021100979A (ja) 2021-07-08
PH12015502153A1 (en) 2016-01-25
JP7249374B2 (ja) 2023-03-30
CN109925312A (zh) 2019-06-25
GB2540638A8 (en) 2017-03-15
IL267997A (en) 2019-09-26
JP6865254B2 (ja) 2021-04-28
US20160220540A1 (en) 2016-08-04
AU2014233363B2 (en) 2017-06-29
CN105307498B (zh) 2019-04-16
GB2516561B (en) 2016-03-09
GB2516561A (en) 2015-01-28
GB2540638A (en) 2017-01-25
US20180237429A1 (en) 2018-08-23
US20160220541A1 (en) 2016-08-04
ES2766326T3 (es) 2020-06-12
GB201411935D0 (en) 2014-08-20
US20180237431A1 (en) 2018-08-23
HK1206558A1 (en) 2016-01-15
GB2540638B (en) 2018-01-17
GB2549865A (en) 2017-11-01
PH12015502153B1 (en) 2019-11-29
BR112015023753A2 (pt) 2017-07-18
GB201520656D0 (en) 2016-01-06
JP2019218370A (ja) 2019-12-26
EP3607821A1 (en) 2020-02-12
GB2549865B (en) 2018-01-17
US20200361926A1 (en) 2020-11-19
MX371382B (es) 2020-01-28
CN105307498A (zh) 2016-02-03
EP4101297A1 (en) 2022-12-14
KR20150129019A (ko) 2015-11-18
US20220274976A1 (en) 2022-09-01
PH12019502018A1 (en) 2020-07-06
IL240786B (en) 2019-07-31
GB201709419D0 (en) 2017-07-26
US20180251457A1 (en) 2018-09-06
US20140275103A1 (en) 2014-09-18
WO2014145068A1 (en) 2014-09-18
MX2015011131A (es) 2016-03-04
CA2903871A1 (en) 2014-09-18
ES2928162T3 (es) 2022-11-15
AU2017235953B2 (en) 2019-12-05
JP6572201B2 (ja) 2019-09-04
EP3607821B1 (en) 2022-08-03
US20180237430A1 (en) 2018-08-23
EP2967066A4 (en) 2016-11-02

Similar Documents

Publication Publication Date Title
PH12019502018A1 (en) Compositions, formulations and methods for treating ocular diseases
PH12019501321A1 (en) Methods of treating or preventing cholesterol related disorders
MX2016002544A (es) Compuestos utiles como inmunomoduladores.
LT3319993T (lt) Axl specifiniai antikūno-vaistokonjugatai, skirti vėžiui gydyti
EP3566750A3 (en) Conjugates comprising cell-binding agents and cytotoxic agents
NZ724691A (en) Quinoline derivatives as smo inhibitors
MX377916B (es) Compuestos 4-amino-imidazoquinolina.
NZ724878A (en) Compounds and compositions as toll-like receptor 7 agonists
EA201991772A1 (ru) Способ лечения рака предстательной железы с использованием комбинации на основе модулятора андрогенного рецептора
MX340090B (es) Analogos de spliceostatina.
HK1216175A1 (zh) 治療性化合物和組合物
MX390503B (es) Compuesto de pirimidina fusionada o sal del mismo.
SA519410320B1 (ar) مركبات فينيل -2-هيدروكسي-أسيتيل أمينو -2-ميثيل-فينيل
PH12016501160A1 (en) Isochromene derivatives as phosphoinositide 3-kinases inhibitors
MX2016009663A (es) Derivados de icariina.
MX373129B (es) Derivados de indolizina como inhibidores de fosfoinositido-3 cinasas.
WO2014134457A3 (en) Conjugates comprising cell-binding agents and cytotoxic agents
HK1219423A1 (zh) 包含细胞结合剂及细胞毒素剂的轭合物
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
MX382092B (es) Compuestos heterocíclicos para el tratamiento de enfermedades.
PH12016500824A1 (en) Compositions and methods for the treatment of viral diseases with pde4 modulators
MX2015012393A (es) Derivados oxindol con un sustituyente oxetano y uso de los mismos para tratar enfermedades relacionadas con la vasopresina.